 |
|
Treatment of Cancer-Associated Hypercalcemia With Cisplatin
Thomas E. Lad, MD;
Howard M. Mishoulam, MD;
Daniel H. Shevrin, MD;
Lawrence J. Kukla, MD;
Edith C. Abramson, MD;
Subhash C. Kukreja, MD
Arch Intern Med. 1987;147(2):329-332.
Abstract
• Cisplatin (cis-platinum) has been shown to lower cancerassociated humoral hypercalcemia in an animal model and to inhibit bone resorption in vitro. This prospective study was designed to evaluate the efficacy of cisplatin in treating cancer-associated hypercalcemia in humans. Thirteen patients with severe hypercalcemia refractory to rehydration were treated with a 24-hour infusion of cisplatin, 100 mg/m2. Serial measurements of serum calcium and tumor size were made following cisplatin treatment and compared with pretreatment values. Nine patients (69%) achieved normocalcemia after treatment with cisplatin; and mean duration of benefit was 38 days in these patients. No reduction in tumor size was seen. All patients died of progressive cancer. We conclude that cisplatin can control malignant hypercalcemia for relatively long periods, and that its mechanism of action is not due to a reduction in tumor size.
(Arch Intern Med 1987;147:329-332)
Author Affiliations
From the Sections of Medical Oncology (Drs Lad, Mishoulam, Shevrin, and Kukla) and Endocrinology (Drs Abramson and Kukreja), Department of Medicine, West Side Veterans Administration and University of Illinois Hospitals, University of Illinois College of Medicine, Chicago.
Footnotes
Accepted for publication July 1, 1986.
Reprint requests to Medical Oncology Section (MP 111), Veterans Administration West Side Medical Center, PO Box 8195, Chicago, IL 60680 (Dr Lad).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Cisplatin as an active treatment in zoledronate-refractory hypercalcemia
Lin et al.
Ann Oncol 2011;22:1244-1246.
FULL TEXT
The Endocrine Effects of Nonhormonal Antineoplastic Therapy
Yeung et al.
Endocr Rev 1998;19:144-172.
ABSTRACT
| FULL TEXT
To the Editor.--
Heiselman
Arch Intern Med 1987;147:1361-1361.
ABSTRACT
Hypercalcemia of Malignancy
Bennett
Arch Intern Med 1987;147:1357-1361.
ABSTRACT
To the Editor.---Reply
Lad et al.
Arch Intern Med 1987;147:1361-1361.
ABSTRACT
|
